State programs assisting pharmacy professionals with substance use disorders

Light, Kim E.; Goodner, Karen; Seaton, Victoria A.; Boyle, Bethany; Hopkins, Robert

doi:10.1016/j.japh.2017.07.002

Cited by 6 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…110 , 111 Pharmacists, however, should systematically screen and assess all patients for substance misuse, SUD, work with community harm reduction groups to decrease harm associated with opioid misuse, and treat patients with SUD, ideally in collaboration with other SUD providers. Pharmacy students themselves are at high risk of substance use disorders, 112 bringing more urgency to insuring that all pharmacists possess the skills, knowledge and attitudes to work with state Boards of Pharmacy and pharmacist recovery networks 113 to help those who have yet to enter the profession as well as their current mentors, preceptors, coworkers, and faculty.…”

Section: Education Licensure and Certificationmentioning

confidence: 99%

Article Commentary: Pharmacy: Addressing Substance use in the 21st Century

Bratberg

2019

Substance Abuse

View full text Add to dashboard Cite

Across all care environments, pharmacists play an essential role in the care of people who use and misuse psychoactive substances, including those diagnosed with substance use disorders. To optimize, sustain, and expand these independent and collaborative roles, the Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA) has developed core competencies for pharmacists to address substance use in the 21st century. Key concepts, skills, and attitudes are outlined, with links to entrustable professional activities to assist with integration into a variety of ideally interdisciplinary curricular activities.

show abstract

Section: Education Licensure and Certificationmentioning

confidence: 99%

Article Commentary: Pharmacy: Addressing Substance use in the 21st Century

Bratberg

2019

Substance Abuse

View full text Add to dashboard Cite

show abstract

“…9 As of 2017, 46 states had a pharmacist-oriented PHP. 10 Three medications have been approved by the U.S. Food and Drug Administration to treat opioid use disorder (OUD): methadone (MTD), buprenorphine (BUP), and naltrexone (NTX). 11 MTD, a full agonist of mu-opioid receptors, was approved to treat opioid dependence in 1972.…”

Section: Introductionmentioning

confidence: 99%

“…As of 2016, 38 U.S. states had a nurse-oriented PHP 9 . As of 2017, 46 states had a pharmacist-oriented PHP 10 …”

Section: Introductionmentioning

confidence: 99%

Policies regarding Use of Medications for Opioid Use Disorder in Professional Recovery Programs: A Scoping Review

et al. 2022

View full text Add to dashboard Cite

Background: In the U.S., medications for opioid use disorder (MOUD) include methadone, buprenorphine, and naltrexone. Despite substantial evidence of efficacy, the use of MOUD by health professionals remains controversial. This scoping review sought to identify and describe policies related to the use of MOUD by physicians, pharmacists, and nurses in professional health programs (PHP). Methods: A systematic search of PubMed, Medline, Web of Science, and Google Scholar was performed in August 2020 to identify pertinent articles from the U.S. which were then evaluated for inclusion by a team of trained reviewers. Results: Nine articles were ultimately identified for inclusion, and their years of publication ranged from 1984 to 2012. The treatment of physicians was addressed in seven articles, nurses in four, and pharmacists in two. Data from one veterinarian and several dentists could not be disaggregated from three studies. Naltrexone was the most commonly accepted form of MOUD within PHPs. A 2011 survey of physician and nurse PHP administrators found that 11/22 (50%) physician programs and 15/33 (45%) nursing programs forbade practice reentry while taking buprenorphine with the remainder indicating it could be allowed under some circumstances. The use of methadone within PHPs was extremely rare, and no specific details regarding PHP policies related to its use or practice reentry could be identified. No articles reported specifically on practice reentry policies for pharmacists. Conclusions: This scoping review identified one article detailing explicit policies concerning MOUD use in the target professions. Implicit policies extrapolated from other articles found that naltrexone was the most commonly accepted form of MOUD, with methadone and buprenorphine being avoided due to dubious concerns of impairment. A unified, contemporary, comprehensive survey of current PHP policies and evaluation of actual treatment data to ascertain real-world practices is needed.

show abstract